



FEMTO TECHNOLOGIES INC.

2264 East 11th Avenue
Vancouver, B.C., Canada
Ph: +1 (604) 833-6820

NEWS RELEASE

Dr. Alexandra Dubinskaya Joins Femto's Sensera as Medical Advisor

Femto's Sensera Combines Intelligent Design, Innovative Technology and Data Driven Insights to Create Its Smart Feminine Wellness Device

LOS ANGELES – JANUARY 22, 2025 - Femto Technologies Inc. (Nasdaq: **BCAN**) (“**Femto**” or the “**Company**”), a FemTech pioneer and the creator of Sensera, a feminine wellness product, today announced that Dr. Alexandra Dubinskaya has joined the company as Medical Advisor for the Sensera brand. Dr. Dubinskaya is a Urogynecologist and Reconstructive Pelvic Surgeon at Cedars Sinai in Los Angeles and a Sexual Medicine Specialist with expertise in menopause and pelvic health.

Sensera's Medical Advisor, Urogynecologist, Reconstructive Pelvic Surgeon, and Sexual Medicine Specialist, Dr. Alexandra Dubinskaya, said: “Sexual wellness is an essential component of overall well-being. Yet, many people are unaware of how to navigate changes in their sexual lives as they age or face health challenges. Sensera is the first sexual wellness product to leverage AI to help users better understand and adjust to these changes, ultimately improving quality of life and intimate experiences.”

Dr. Dubinskaya, along with her colleagues, conducted research highlighting the positive impact vibrating devices can have on sexual function and pelvic floor conditions*. She explained: “Our study demonstrated that vibrating devices could significantly improve sexual function over time. We observed a marked reduction in bothersome symptoms of pelvic organ prolapse, as well as lower pain scores. Additionally, patients with lichen sclerosus showed noticeable improvements in lesion appearance, and the severity of vaginal atrophy decreased. Depression rates were also significantly reduced, underscoring the holistic benefits these devices can offer.”

The findings underscore Femto's mission to integrate innovation with care, empowering individuals to take charge of their intimate health and well-being.

“We are thrilled to welcome Dr. Dubinskaya to the Sensera team,” said Yftah Ben Yaackov, CEO of Femto. “Her unparalleled knowledge and expertise in the area of sexual function, menopause and pelvic

floor health is an asset to the company and to the women who are looking to Sensera to provide intelligent products that bridge the gap between pleasure and wellness.”

Femto’s proprietary technology enables Sensera, a FemTech device, to provide a unique experience designed to adapt to a woman's changing needs over time. Sensera features the brand’s proprietary technology, Smart Release System (SRS), along with biofeedback sensors, machine learning and artificial intelligence, personalizing the feminine usability experience and enhancing comfort.

How It Works:

Sensera’s feminine wellness device is made from soft, medical-grade silicone and features a Y-shaped, ergonomic design. Women can choose a capsule (pleasure or wellness) and insert one of the interchangeable pods into the device with a simple twist. Once the session starts, Sensera’s proprietary SRS technology utilizes biofeedback sensors that track key body metrics, heart rate, and pelvic floor muscle contractions, to adapt to women's personal needs and preferences.

A corresponding iOS app enables users to create personal customized programs, enhancing its performance and ability to “build” on previous sessions.

Under strict privacy protocols, women have the choice to support women’s wellness by sharing their likes, dislikes and feedback to create better, more personalized wellness programs for all. Sensera also offers device-only mode and machine learning-only use. Sensera’s AI capabilities are designed to become more advanced in correlation to the increased volume of users and magnitude of fed data.

Sensera’s feminine wellness device includes a charging cable, storage sachet, quick start guide and three interchangeable pods: two pleasure; one wellness. It will be available for pre-order in Q1 at www.senserawellness.com. Additional capsules can be purchased separately as a one-time order or via subscription. Pre-orders are scheduled to ship early Q2 2025.

###

ABOUT SENSERA

Sensera is a feminine wellness device on a mission to bridge the gap between feminine pleasure and wellness, providing a holistic self-care experience that adapts to a woman’s changing needs. Sensera utilizes Femto’s proprietary Smart Release System (SRS) technology, including machine learning and AI, to enhance feminine wellness. Sensera is a CES Innovation Awards® 2025 Honorary in the AI category.

For more information on Sensera, please visit www.senserawellness.com and follow us on Instagram, Facebook, and YouTube.

ABOUT FEMTO TECHNOLOGIES, INC.

Femto Technologies Inc. (Nasdaq: BCAN), previously known as BYND Cannasoft Enterprises Inc., is a public Femtech company, pioneering a transformative change in the sphere of female wellness. Its proprietary Smart Release System (SRS technology) is embedded in Sensera, which has been named CES Innovation Awards® 2025 honoree in the AI category. Femto’s SRS technology is driving its R&D activities and product manufacturing for a variety of Femtech products.

The devices described in this news release are concept devices that are in the first stage of development and will be subject to testing, experiments and regulatory approvals and therefore there is no certainty that they will eventually be marketed.

For more information, please visit www.femtocorp.com and on SEDAR+: www.sedarplus.ca

MEDIA CONTACT

For product demonstration and media

Samantha Breen

Opportunity PR (for Sensera)

samantha@opportunitypr.com

+1 949.290.2834

COMPANY CONTACT

Gabi Kabazo

Chief Financial Officer

Tel: (604) 833-6820

e-mail: ir@femtocorp.com

*Sensera's device was not used in this study. Dr. Dubinskaya had no relationship with Sensera when this research was conducted.

Sensera encourages you to do your own research and read the full study linked above. This is not intended as medical advice. Discuss any concerns you may have with your doctor.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain statements that may be deemed "forward-looking statements" within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended and under Canadian securities laws. When used in this press release, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such statements reflect the Company's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including future financial performance, unanticipated regulatory requests and delays, final patents approval, timing of the Sensera pre-order and those factors discussed in filings made by the company with the Canadian securities regulatory authorities, including (without limitation) in the company's management's discussion and analysis for the year ended December 31, 2023 and annual information form dated April 2,

2024, which are available under the company's profile at www.sedarplus.ca, and in the Company's Annual Report on Form 20-F for the year then ended that was filed with the U.S. Securities and Exchange Commission on April 3, 2024. Should one or more of these factors occur, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Shareholders are cautioned not to put undue reliance on such forward-looking statements.